Evidence map›Paper›PMID 37491478›Full record

ArticleScientific reports2023

A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).

Thomas Starkey, Maria C Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W Fittall, Sam Khan, Justin K H Liu, James R Platt, Rosie Mew and 53 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.Transplant infectious disease : an official journal of the Transplantation Society · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

63 authors.

Thomas Starkey *Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Maria C Ionescu *UK Health Security Agency, London, UK.
Michael Tilby *University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Martin Little *Oxford University Hospitals NHS Trust, Oxford, UK.
Emma Burke *Oxford University Hospitals NHS Trust, Oxford, UK.
Matthew W Fittall *Cancer Institute, University College London, London, UK.
Sam Khan *University of Leicester, Leicester, UK.
Justin K H Liu *University of Leeds, Leeds, UK.
James R Platt *Leeds Institute of Medical Research at St James's, Leeds, UK.
Rosie Mew *Torbay and South Devon NHS Foundation Trust, Torquay, UK.
Arvind R Tripathy *Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Isabella Watts *Royal Free London NHS Foundation Trust, London, UK.
Sophie Therese Williams *University of Sheffield, Sheffield, UK.
Nathan AppannaOxford Medical School, University of Oxford, Oxford, UK.
Youssra Al-HajjiBirmingham Medical School, University of Birmingham, Birmingham, UK.
Matthew BarnardUK Health Security Agency, London, UK.
Liza BennyUK Health Security Agency, London, UK.
Alexander BurnettWeston Park Cancer Centre, Sheffield, UK.
Jola BytyciDepartment of Oncology, University of Oxford, Oxford, UK.
Emma L CattellTaunton and Somerset NHS Foundation Trust, Taunton, UK.
Vinton ChengUniversity of Leeds, Leeds, UK.
James J ClarkImperial College London, London, UK.
Leonie EastlakeRoyal Cornwall Hospital Trust, Truro, UK.
Kate GerrandUK Health Security Agency, London, UK.
Qamar GhafoorUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Simon GrumettUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Catherine Harper-WynneKent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
Rachel KahnBlood Cancer UK, London, UK.
Alvin J X LeeUniversity College London, London, UK.
Oliver LomasOxford University Hospitals NHS Trust, Oxford, UK.
Anna LydonTorbay and South Devon NHS Foundation Trust, Torquay, UK.
Hayley MckenzieUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
NCRI Consumer Forum
Hari PanneerselvamWye Valley NHS Trust, Hereford, UK.
Jennifer S PascoeUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Grisma PatelUniversity College London, London, UK.
Vijay PatelNational Health Service, London, UK.
Vanessa A PotterUniversity Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Amelia RandleRoyal College of Physicians, London, UK.
Anne S RiggGuy's and St Thomas' NHS Foundation Trust, London, UK.
Tim M RobinsonUniversity of Bristol, Bristol, UK.
Rebecca RoylanceUniversity College London Hospitals NHS Foundation Trust, London, UK.
Tom W RoquesNorfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
Stefan RozmanowskiUK Health Security Agency, London, UK.
René L RouxOxford University Hospitals NHS Trust, Oxford, UK.
Ketan ShahOxford University Hospitals NHS Trust, Oxford, UK.
Remarez SheehanNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Martin SintlerSandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
Sanskriti SwarupDepartment of Oncology, University of Oxford, Oxford, UK.
Harriet TaylorOxford Medical School, University of Oxford, Oxford, UK.
Tania TillettRoyal United Hospital Bath NHS Trust, Bath, UK.
Mark TuthillOxford University Hospitals NHS Trust, Oxford, UK.
Sarah WilliamsUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Yuxin YingDepartment of Oncology, University of Oxford, Oxford, UK.
Andrew BeggsInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Tim IvesonUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Siow Ming LeeUniversity College London Hospitals NHS Foundation Trust, London, UK.
Gary MiddletonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Mark MiddletonDepartment of Oncology, University of Oxford, Oxford, UK.
Andrew ProtheroeChurchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Tom FowlerUK Health Security Agency, London, UK.
Peter JohnsonUniversity of Southampton, Southampton, UK.
Lennard Y W LeeInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. lennard.lee@oncology.ox.ac.uk.

Funding

Cancer Research UK 28990Cancer Research UK 30195Department of Health
6 · The paper itself

Abstract

Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

Indexed as

COVID-19NeoplasmsAdolescentAdultAgedAged, 80 and overCase-Control StudiesEnglandFemaleHumansMaleMiddle AgedTreatment OutcomeYoung Adult

Identifiers

PMID37491478
PMCPMC10368624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.